Scarica l'app Stockscreener
1.40
19.40%
0.24
Precedente Chiudi:
$1.16
Aprire:
$1.2
Volume 24 ore:
13.04M
Relative Volume:
0.83
Capitalizzazione di mercato:
$211.74M
Reddito:
$424.90K
Utile/perdita netta:
$-94.02M
Rapporto P/E:
-0.5636
EPS:
-2.4842
Flusso di cassa netto:
$-51.25M
1 W Prestazione:
+96.54%
1M Prestazione:
+507.19%
6M Prestazione:
-43.93%
1 anno Prestazione:
-21.75%
Intervallo 1D:
$1.17
$1.44
Intervallo di 1 settimana:
$0.697
$1.42
Portata 52W:
$0.1611
$3.39
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Nome
Outlook Therapeutics Inc
Settore
Industria
Telefono
(609) 619-3990
Indirizzo
111 S. WOOD AVENUE, ISELIN, NJ
Compare OTLK vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
1.425 | 172.36M | 424.90K | -94.02M | -51.25M | -2.4842 |
VRTX
Vertex Pharmaceuticals Inc
|
450.39 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
611.72 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
875.97 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.58 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.13 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-29 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-08-28 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-12-02 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2024-03-27 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2024-02-15 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2024-01-25 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-12-27 | Aggiornamento | CapitalOne | Equal Weight → Overweight |
| 2023-08-31 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2023-08-31 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-08-30 | Downgrade | BTIG Research | Buy → Neutral |
| 2023-08-30 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-08-30 | Downgrade | CapitalOne | Overweight → Equal Weight |
| 2023-08-30 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-07-13 | Iniziato | CapitalOne | Overweight |
| 2023-04-03 | Iniziato | Guggenheim | Buy |
| 2023-02-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-10-31 | Iniziato | BTIG Research | Buy |
| 2022-09-13 | Iniziato | Chardan Capital Markets | Buy |
| 2019-09-11 | Iniziato | Ladenburg Thalmann | Buy |
| 2019-05-16 | Iniziato | Oppenheimer | Outperform |
| 2019-04-22 | Iniziato | Ascendiant Capital Markets | Buy |
Mostra tutto
Outlook Therapeutics Inc Borsa (OTLK) Ultime notizie
Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD - Yahoo Finance Singapore
Outlook Therapeutics Surges As FDA Fast-Tracks ONS-5010 Review - timothysykes.com
Why Outlook Therapeutics (OTLK) Is Up 57.1% After FDA Validates LYTENAVA Efficacy and BLA Resubmission - Yahoo Finance Singapore
OTLK Stock Surges On FDA Lytenava Application Resubmission After Successful Appeal - Stocktwits
OTLK Jumps As Outlook Therapeutics Wins FDA Backing On BLA Resubmission - timothysykes.com
symbol__ Stock Quote Price and Forecast - CNN
OTLK Stock Jumps As FDA Fast-Tracks Lytenava Review - timothysykes.com
OTLK Stock Jumps As FDA Fast-Tracks Lytenava Resubmission - StocksToTrade
OTLK Stock Jumps As FDA Fast-Tracks Lytenava Decision - timothysykes.com
Why Is OTLK Stock Falling Today? - Stocktwits
📈📈📈📈📈📈📈📈📈📈📈📈📈📈📈📈📈📈📈 - Moomoo
OTLK Maintained by Ascendiant Capital -- Price Target Raised to $10.00 - GuruFocus
Outlook Therapeutics Gains as FDA Timeline for Lytenava Comes Up - TechStock²
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
OTLK stock surges over 50% pre-market, breaches key technical milestone – what’s behind this massive rally? - MSN
Outlook Therapeutics gains on FDA appeal win, boosting chances for Lytenava approval. - Pluang
Outlook Therapeutics: Potential Catalysts Offering An Arbitrage Opportunity (NASDAQ:OTLK) - Seeking Alpha
Outlook Therapeutics director Haddadin Yezan Munther buys $24,145 in shares - Investing.com UK
Outlook Therapeutics director Haddadin Yezan Munther buys $24,145 in shares By Investing.com - Investing.com South Africa
Outlook Therapeutics (OTLK) Stock Forum and Discussion - Moomoo
Director at Outlook Therapeutics (NASDAQ: OTLK) buys 29,000 shares - Stock Titan
OTLK stock surges on FDA Lytenava application resubmission after successful appeal - MSN
Outlook Therapeutics Resubmits FDA Application for ONS-5010 - The Globe and Mail
$Outlook Therapeutics (OTLK.US)$ Looking forward to seeing what you can do tonight. - Moomoo
Outlook Therapeutics director’s firm buys $5m in common stock - Investing.com UK
Outlook Therapeutics director’s firm buys $5m in common stock By Investing.com - Investing.com South Africa
GMS Ventures lifts Outlook Therapeutics (OTLK) stake in $5M share deal - Stock Titan
[SCHEDULE 13D/A] Outlook Therapeutics, Inc. Amended Major Shareholder Report - Stock Titan
Outlook Therapeutics resubmits drug application to FDA - Investing.com UK
Outlook resubmits wet AMD BLA for bevacizumab after FDA appeal win - Eyes On Eyecare
Outlook Therapeutics (NASDAQ: OTLK) seeks approval for reverse split and major share increase - Stock Titan
Outlook Therapeutics resubmits drug application to FDA By Investing.com - Investing.com South Africa
Outlook Therapeutics (OTLK) Resubmits Biologics License Applicat - GuruFocus
Outlook Therapeutics, Inc. Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA? (bevacizumab-vikg) - marketscreener.com
Outlook Therapeutics (Nasdaq: OTLK) resubmits FDA BLA with 60-day review - Stock Titan
Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg) - The Manila Times
U.S. FDA receives ONS-5010 Biologics License Application from Outlook Therapeutics - Traders Union
Outlook Therapeutics Announces Resubmission of Biologics - GlobeNewswire
Outlook Therapeutics Inc Azioni (OTLK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Outlook Therapeutics Inc Azioni (OTLK) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Sukhtian Ghiath M. | Director |
May 28 '26 |
Buy |
0.59 |
8,539,709 |
5,000,000 |
22,092,068 |
| Sukhtian Faisal Ghiath | Director |
May 27 '26 |
Buy |
0.41 |
122,174 |
50,006 |
125,574 |
| Haddadin Yezan Munther | Director |
May 26 '26 |
Buy |
0.44 |
34,000 |
14,960 |
37,167 |
| THURMAN RANDY H | Director |
May 26 '26 |
Buy |
0.43 |
5,000 |
2,145 |
5,593 |
| HILZINGER KURT J | Director |
May 26 '26 |
Buy |
0.44 |
400,000 |
176,520 |
423,655 |
1.61%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):